Annexon, Inc.

NASDAQ:ANNX

Biotechnology

Healthcare
$3.47 -0.71%

-$0.04 today

Market cap
$568.53M
Beta
1.18
P/E (TTM)
-4.8
EPS (TTM)
-$1.01
52W Low $1.85High $7.18

Volume 2.88M

Average 2.56M

ANNX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Annexon, Inc.NASDAQ: ANNX

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$43.19M, compared with -$53.82M a year earlier. Trailing-twelve-month EBITDA was -$193.41M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -51.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.19M+8.7% QoQ
Last fiscal yearDec 2025
-$204.04M-51.4% YoY
LTMMar 2026
-$193.41M-17.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.8%+100.0%+80.2 pp
1 year-51.4%+100.0%+151.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(204.04M) USD
Year-over-year change
-51.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ANNX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.1% is the 8th highest of 11, against a peer median of -9.9%.
ANNX Competitors
EBITDA for ANNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M USD+176.6%—25.2%
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M USD+154.8%—41.2%
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
ACIUAC Immune S.A.LTM Mar 2026-CHF 64.45M CHF-29.6%—1740.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M USD-31.5%—843.9%
PRTAProthena Corporation plcLTM Mar 2026-$74.72M USD+35.0%—129.0%
XNCRXencor, Inc.LTM Jun 2026-$123.6M USD-14.3%—117.7%
ANNXAnnexon, Inc.LTM Mar 2026-$193.41M USD-17.1%——
ABVXAbivax S.A.FY2025-€300.7M EUR-84.8%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M USD-9.5%—5986.3%
IMVTImmunovant, Inc.LTM Sep 2026-$509.88M USD-10.4%—7186.4%
Peer median (excluding ANNX) —-9.9%—843.9%

Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0003.45M3.69M
Gross Profit000(3.45M)(3.69M)
Gross Margin—————
Research & Development100.07M112.5M113.76M119.45M184.7M
Selling, General & Admin30.65M30.95M28.02M34.63M31.71M
Operating Expenses130.71M145.6M143.72M150.62M212.72M
Depreciation & Amortization2.14M2.15M2.15M3.45M2.65M
EBITDA(128.18M)(139.8M)(132.09M)(134.75M)(204.04M)
EBITDA Margin—————
Operating Income(130.71M)(145.6M)(143.72M)(154.07M)(216.41M)
Operating Margin—————
Interest Income390K3.65M9.49M15.87M9.72M
Interest Expense00000
Other Income / Expenses390K3.65M9.49M15.87M9.72M
Income Before Tax(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(130.32M)(141.95M)(134.24M)(138.2M)(206.69M)
Net Margin—————
EPS (Basic)(3.34)(2.60)(1.77)(1.01)(1.34)
EPS (Diluted)(3.34)(2.60)(1.77)(1.01)(1.34)
Weighted Avg Shares38.32M54.67M75.67M137.4M155.11M
Weighted Avg Shares (Diluted)38.32M54.67M75.67M137.4M155.11M

Annexon, Inc.

NASDAQ:ANNX

Intrinsic Alpha fair value

Locked

Current Price

$3.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.